Anaphylaxis can be a life-threatening reaction to an allergen The FDA has approved a nasal spray, neffy, as the first non-needle means of delivering rescue epinephrine during anaphylaxis The spray is meant for adults and kids weighing over 66 pounds FRIDAY, Aug. 9, 2024 (HealthDay News) -- Folks nervous about administering a rescue shot for anaphylaxis finally have a new alternative in a nasal spray. The U.
S. Food and Drug Administration on Friday announced that it has approved neffy, the first non-injected treatment for life-threatening allergic reactions. The epinephrine nasal spray is for use by adults and children who weigh more than 66 pounds, the agency said.
"Anaphylaxis is life-threatening and some people, particularly children, may delay or avoid treatment due to fear of injections,” Dr. Kelly Stone, associate director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in an . “The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis.
As a result, neffy provides an important treatment option and addresses an unmet need.” Folks with can experience a sudden, frightening reaction to allergens -- often certain foods, medications or insect stings. Until now, epinephrine has been the only rescue medication when such incidents occur, and it's only been administered via a needle.
Neffy, made by ARS Pharmaceuticals, is delivered as a spray spritzed into one nostr.